Skip to content

Restoration of CD4 T-cells limited in children starting HIV treatment at low CD4 percentages

CROI: Persistent brain impairment despite HIV treatment linked to severity of prior dementia

CROI: Atazanavir and atazanavir/ritonavir safe and effective in treatment-naive patients

CROI: Simplified treatment regimens show promise in HIV-infected children

Immune reconstitution syndrome risk highest in those commencing HIV therapy with advanced HIV disease

Treatment interruption study stopped after excess number of AIDS events seen in people taking treatment breaks

ICAAC: Nevirapine’s manufacturer examines rates of liver toxicity in key study, finds once daily dose equally safe at lower CD4 count

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy

ICAAC: TB patients with good CD4 cell counts can safely defer HIV treatment